



## Tolebrutinib for Secondary Progressive Multiple Sclerosis: Effectiveness and Value

Friday • June 13, 2025 • 9:00 AM PT

Virtual Event – Zoom Webinar

Time (PT)	Activity
9:00 AM—9:20 AM	<b>Meeting Convened and Opening Remarks</b> Sarah K. Emond, MPP, President and CEO, ICER
9:20 AM—10:00 AM	<b>Presentation of the Clinical Evidence</b> Grace Lin, MD, MAS Medical Director for Health Technology Assessment, ICER Associate Professor of Medicine and Health Policy, UCSF
10:00 AM—10:40 AM	<b>Presentation of the Economic Model</b> Brett McQueen, PhD Associate Professor, University of Colorado Anschutz Medical Campus
10:40 AM—11:00 AM	<b>Public Comments and Discussion</b>
11:00 AM—11:45 AM	<b>Lunch Break</b>
11:45 AM—12:45 PM	<b>CTAF Vote on Clinical Effectiveness and Value</b> Moderator: Ralph G. Brindis, MD, MPH, MACC, FSCAI, FAHA, Clinical Professor of Medicine at the University of California, San Francisco (UCSF)
12:45 PM—1:00 PM	<b>Break</b>
1:00 PM—2:30 PM	<b>Policy Roundtable</b> Moderator: Sarah K. Emond, MPP, President and CEO, ICER
2:30 PM—3:00 PM	<b>Reflections from CTAF</b>
3:00 PM	<b>Meeting Adjourned</b>

Connect with ICER on our social media channels

